¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"time study"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • retention time
    Á¤Ã¼½Ã°£
  • rise time
    »ó½Â½Ã°£
  • spin lattice relaxation time
    ½ºÇɰÝÀÚÀ̿Ͻð£
  • spin-spin relaxation time
    ½ºÇɽºÇÉÀ̿Ͻð£
  • survival time
    »ýÁ¸±â°£
  • synaptic time
    ½Ã³À½ºÅë°ú½Ã°£, ¿¬Á¢Åë°ú½Ã°£
  • sedimentation time
    ħ°­½Ã°£
  • sinoatrial conduction time
    ±¼½É¹æÀüµµ½Ã°£, µ¿½É¹æÀüµµ½Ã°£
  • sinus node recovery time
    ±¼°áÀýȸº¹½Ã°£, µ¿°áÀýȸº¹½Ã°£
  • tear film breakup time
    ´«¹°¸·ÆÄ±«½Ã°£
  • utilization time
    ÀÌ¿ë½Ã°£
  • ventricular activation time
    ½É½ÇÈïºÐ½Ã°£
  • voiding time
    ¹è´¢½Ã°£
  • zero-time shift
    ¿øÁ¡À̵¿
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • tension time index
    Àå·Â½Ã°£°è¼ö
  • time interval
    ½Ã°£°£°Ý
  • latent time
    Àẹ½Ã°£
  • lead time
    Á¶±â¹ß°ß±â°£
  • maximum phonation time
    ÃÖÀå¹ß¼ºÁö¼Ó½Ã°£
  • mean survival time
    Æò±Õ»ýÁ¸½Ã°£
  • mean tidal time
    Æò±Õ¼øÈ¯½Ã°£
  • time dependent relative risk model
    ½Ã°£ÀÇÁ¸»ó´ëÀ§Çè¸ðµ¨
  • partial thromboplastin time
    ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
  • peak concentration time
    ÃÖ°í³óµµ½Ã°£
  • perception time
    Áö°¢½Ã°£, ÀνĽð£
  • person-time incidence rate
    »ç¶÷±â°£¹ß»ý·ü
  • phonation time
    ¹ß¼ºÁö¼Ó½Ã°£
  • polymerizing time
    ±»´Â½Ã°£, ÁßÇսð£
  • potential doubling time
    ÀáÀç¹è°¡½Ã°£
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • gastric emptying time
    À§(êÖ)(³»¿ë(Ò®é»))¹èÃâ½Ã°£(ÛÉõóãÁÊà).
  • gastric emptying time
    À§(³»¿ë)¹èÃâ½Ã°£.
  • generation time =doubling t.
    ¼¼´ë½Ã°£(á¦ÓÛãÁÊà), ¹èÀ§½Ã°£(ÛÃêÈãÁÊà), ¼¼´ë±â(á¦ÓÛÑ¢).
  • half survival time
    ¹Ý°¨ÀÜ»ý¼ö¸í(ËÑ˧ ËÛËÎ).
  • half survival time
    ¹Ý°¨ÀÜ»ý¼ö¸í(ÚâÊõíÑßæáøÙ¤).
  • half time for saturation
    ¹ÝÆ÷È­±â(ÚâøéûúÑ¢).
  • hardening time
    °æÈ­½Ã°£(¡­ãÁÊà).
  • inertia time
    Ÿ¼º½Ã°£(öçàõãÁÊà)
  • influx time
    À¯ÀԽð£(êüìýãÁÊà).
  • inspiratory pause time
    Èí±âÈÄÈÞÁö½Ã°£.
  • inspiratory phase time
    Èí±â»ó½Ã°£.
  • inspiratory triggering response time
    Èí±âÀ¯¹ß¹ÝÀÀ½Ã°£.
  • interaural time difference
    ¾çÀ̰£ µµ´Þ½Ã°£Â÷
  • intercostal real-time scanning
    ´Á°£ ½Ç½Ã°£ (ÒñÊà ãùãÁÊà) ½ºÄµ
  • intercostal real-time scanning
    ´Á°£ ½Ç½Ã°£ ½ºÄµ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
TD the time required to double the number of cells in a given population; thermal death time
TDT terminal deoxynucleotidyltransferase; thermal death time; tone decay test; tumor doubling time
TE exhalation time; expiratory phase time
TI inversion time; temporal integration; terminal ileum; thalassemia intermedia; therapeutic index; tho...
TL temporal lobe; terminal limen; thermolabile; thermoluminescence; threat to life; thymus-leukemia [an...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
EPS Electrophysiologic study
EPESE Epidemiologic Study of the Elderly
ESSG European Spondylarthropathy Study Group
EVOS European Vertebral Osteoporosis Study
FATS Familial Atherosclerosis Treatment Study
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 7
time sense The faculty by which the passage of time is appreciated.
(05 Mar 2000)
time-varied gain In ultrasonography, an increase in receiver gain with time to compensate for loss in echo amplitude with depth, usually due to attenuation.
Synonym: attenuation compensation, depth compensation, time compensation gain, time-compensated gain, time-varied gain control, time-varied gain.
(05 Mar 2000)
time-varied gain control In ultrasonography, an increase in receiver gain with time to compensate for loss in echo amplitude with depth, usually due to attenuation.
Synonym: attenuation compensation, depth compensation, time compensation gain, time-compensated gain, time-varied gain control, time-varied gain.
(05 Mar 2000)
tissue thromboplastin inhibition time A test used to identify lupus anticoagulant; the thromboplastin source used in the prothrombin test is diluted to increase sensitivity to inhibitors.
(05 Mar 2000)
energy confinement time <radiobiology> Characteristic time in which 1/e (or sometimes 1/2) of a system's energy is lost to its surroundings.
In a plasma device, the energy loss time (or the energy confinement time) is one of three critical parameters determining whether enough fusion will occur to sustain a reaction.
See: Lawson criterion.
(09 Oct 1997)
energy replacement time <radiobiology> Time required for a plasma to lose (via radiation or other loss mechanisms) an amount of energy equal to its average kinetic energy.
(09 Oct 1997)
euglobulin clot lysis time A measure of the ability of plasminogen activators and plasmin to lyse a clot; normally, clot lysis is determined by the balance of factors which activate fibrinolysis (plasminogen activators and plasmin) and those which inhibit lysis; in certain conditions (e.g., carcinoma or hepatic insufficiency) activating factors predominate and can be measured by noting the time it takes the euglobulin fraction of plasma (excluding inhibitors of fibrinolysis) to clot.
(05 Mar 2000)
fading time The time required for a constant stimulus applied to a fixed area of the peripheral visual field to stop.
(05 Mar 2000)
zero time-binding DNA DNA that has become the duplex form at the start of a reassociation process.
Acronym: DNA
(05 Mar 2000)
utilization time The minimum duration of a stimulus of rheobasic strength that is just sufficient to produce excitation.
Synonym: temps utile.
(05 Mar 2000)
forced expiratory time The time taken to expire a given volume or a given fraction of vital capacity during measurement of forced vital capacity; subscripts specify the exact parameters measured.
(05 Mar 2000)
left ventricular ejection time The time measured clinically from onset to incisural notch of the carotid or other pulse; properly the time of ejection of blood from the left ventricle beginning with aortic valve opening and ending with aortic valve closure.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • pulse time modulation
    ÆÞ½º½Ã º¯Á¶
  • question time
    Áú¹® ½Ã°£
  • quick time
    ¼Óº¸;1½Ã°£ 4¸¶ÀÏ
  • ragged time
    (³ëÁ£±â µîÀÌ)°í¸£Áö ¾ÊÀ½
  • reaction time
    ¹ÝÀÀ ½Ã°£
  • real time
    ½Ç½Ã°£;Áï½Ã ÀÀ´ä(»ç»ó°ú ±× µ¥ÀÌÅÍ Ã³¸®°¡ °°Àº ¼Óµµ·Î 󸮵Ê);Áï½Ã;µ¿½Ã
  • real-time
    ½Ç½Ã°£ÀÇ;(±â·Ï.¹æ¼ÛµîÀÌ)Áï½ÃÀÇ;µ¿½ÃÀÇ
  • real-time system
    ½Ç½Ã°£(Áï½Ãó¸®)½Ã½ºÅÛ(´Ü¸»¿¡¼­ º¸³»¿Â µ¥ÀÌÅ͸¦ Áï½Ã ÄÄÇ»ÅÍ¿¡ ó¸®ÇÏ¿© ´Ü¸»·Î µÇµ¹¸®´Â ½Ã½ºÅÛ)
  • released time
    ±³¿Ü Á¾±³ ±³À° µîÀ» À§ÇÑ ÀÚÀ¯ ½Ã°£
  • response time
    ÀÀ´ä ½Ã°£
  • reverberating time
    ÀÜÇâ½Ã°£
  • short time
    Á¶¾÷ ´ÜÃà
  • small time
    (ÇÏ·ç¿¡ ¸î¹ø¾¿ »ó¿¬ÇÏ´Â)½Î±¸·Á ¿¬¿¹(¿¬±Ø)
  • standard time
    Ç¥ÁؽÃ
  • straight time
    ±ÔÁ¤ ³ëµ¿½Ã°£
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
ÅëÇÕ°Ë»ö ¿Ï·á